Providing Better Patient Care: Series XVII

February 20-22, 2013
Earn up to 15 hours of continuing education credit.

Session 1 – Cardiovascular Risk Reduction in Primary Prevention

Date: 2/20/2013
Check-in and Breakfast: 7:00am - 7:30am
Educational Session: 7:30am - 1:00pm

At the conclusion of this program, the participant should be able to:

Review current JNC 8 guideline recommendations for the management of hypertension in primary prevention patients.
Identify changes in the JNC 8 that impact the treatment of hypertension in all patients.
Explain the evidence that supports JNC 8 guideline recommendations related to antihypertensive pharmacotherapy.

Review current NCEP ATP IV guideline recommendations for the management of dyslipidemia in primary prevention patients.

Identify changes in the ATP IV that impact the treatment of dyslipidemia in primary prevention.

Explain the evidence that supports ATP IV guideline recommendations related to statin-based lipid lowering pharmacotherapy.

Review the USPSTF recommendations for aspirin therapy in primary prevention of CV events.

Debate current controversies regarding the lack of evidence supporting aspirin therapy in the primary prevention of CV events.

Describe other benefits related to aspirin therapy in primary prevention patients.

Identify other treatment strategies to reduce risk of CV events in primary prevention patients.

When given a case scenario of a primary prevention patient, provide pharmacotherapy recommendations designed to reduce risk of CV events.

Joseph Saseen, Pharm.D., FCCP, FNLA, BCPS, CLS
Professor, Clinical Pharmacy and Family Medicine, University of Colorado School of Pharmacy & School of Medicine.